A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.

In a comparative double-blind trial involving 263 postmenopausal women with advanced breast cancer treated with tamoxifen, the mean objective tumour response rate and duration was 32% and 15 months respectively. No significant difference was found in clinical response and adverse effects between those randomised to 10 mg and those to 20 mg twice daily. Although the mean serum concentration of tamoxifen in the 20 mg bd group was significantly higher no correlation between serum level and clinical benefit was demonstrated.

• Publication year

  1984

• Venue

  British Journal of Cancer

• Publication date

  1984-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bjc.1984.163PMID 6380554PMCID 1976875
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No evidence of differential effects of SFA, MUFA or PUFA on post-ingestive satiety and energy intake: a randomised trial of fatty acid saturation

  2010cited by this paper
• Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research.

  1983cited by this paper
• Trial of tamoxifen at a dose of 40 mg daily after disease progression during tamoxifen therapy at a dose of 20 mg daily.

  1982cited by this paper
• Chemotherapy and tamoxifen for breast cancer.

  1981cited by this paper
• Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: A randomized trial

  1980cited by this paper
• Serum concentrations of tamoxifen and major metabolite during long-term nolvadex therapy, correlated with clinical response.

  1980cited by this paper
• Measurement of tamoxifen in serum by thin-layer densitometry.

  1980cited by this paper
• Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function.

  1980cited by this paper
• Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers.

  1980cited by this paper
• Tamoxifen in advanced breast cancer.

  1978cited by this paper
• Assessment of response to therapy in advanced breast cancer (an amendment)

  1978cited by this paper
• Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland.

  1978cited by this paper
• Antiöstrogene Therapie des metastasierenden Mammakarzinoms*

  1977cited by this paper
• [Anti-oestrogen treatment of metastasising carcinoma of the breast (author's transl)].

  1977cited by this paper
• Assessment of response to therapy in advanced breast cancer.

  1977cited by this paper
• Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer.

  1976cited by this paper
• Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels

  1973cited by this paper

• Impact of Irradiation on the Pharmacokinetics and Biotransformation of Tamoxifen

  2022cites this paper
• Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer

  2021cites this paper
• Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors

  2021cites this paper
• Endocrine Therapy for Breast Cancer

  2018cites this paper
• Does CYP2D6 Genotyping have a Role in Guiding Tamoxifen Therapy

  2017cites this paper
• Terapia antiestrogénica en los cánceres de mama

  2016cites this paper
• Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective.

  2015cites this paper
• Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer

  2015cites this paper
• Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen

  2015cites this paper
• Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis.

  2014cites this paper
• Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care

  2014cites this paper
• Bioanalysis and clinical pharmacology of tamoxifen in breast cancer

  2014cites this paper
• Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance

  2012influential citation
• Use of preclinical and early clinical data for dose selection of a selective estrogen receptor modulator toremifene in treatment of breast cancer

  2012cites this paper
• Hormonothérapie des cancers du sein en situation adjuvante et métastatique et néo-adjuvante

  2012cites this paper
• Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment

  2011cites this paper
• Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.

  2011cites this paper
• UDP-glucuronosyltransferase 2B7 glucuronidation of the active tamoxifen metabolites

  2011cites this paper
• In vitro metabolic interactions between black cohosh (Cimicifuga racemosa) and tamoxifen via inhibition of cytochromes P450 2D6 and 3A4

  2011cites this paper
• CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.

  2011cites this paper
• Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy.

  2010cites this paper
• Tamoxifen Malabsorption After Roux‐en‐Y Gastric Bypass Surgery: Case Series and Review of the Literature

  2010cites this paper
• Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literature.

  2010cites this paper
• Targeted Approaches to Drug Development

  2009cites this paper
• CYP2D6 and tamoxifen: DNA matters in breast cancer

  2009cites this paper
• Use of Antidepressants in Patients with Breast Cancer Taking Tamoxifen

  2009cites this paper
• Genotype-guided tamoxifen therapy: time to pause for reflection?

  2009cites this paper
• Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response

  2008cites this paper
• Interaction of antiestrogens with binding sites for muscarinic cholinergic drugs and calcium channel blockers in cell membranes

  2008cites this paper
• Tamoxifen: using pharmacogenetics to rediscover an old drug

  2007cites this paper
• Letrozole in advanced breast cancer: the PO25 trial

  2007cites this paper
• Focus On Tamoxifen: using pharmacogenetics to rediscover an old drug

  2007cites this paper
• Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer.

  2007cites this paper
• Endocrine therapy for breast cancer

  2006cites this paper
• Der Einfluss genetischer Polymorphismen auf die Wirksamkeit von Medikamenten unter besonderer Berücksichtigung onkologischer Therapien

  2006cites this paper
• Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes.

  2006cites this paper
• Special Lecture Development of Antiestrogens and Their Use in Breast Cancer : Eighth Cain Memorial Award Lecture 1

  2006cites this paper
• State of the Art der endokrinen Therapie des metastasierten Mammakarzinoms

  2005influential citation
• CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

  2005cites this paper
• Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial

  2004cites this paper
• Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6

  2004cites this paper
• A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen

  2004cites this paper
• Mifepristone Induces Growth Arrest, Caspase Activation, and Apoptosis of Estrogen Receptor-Expressing, Antiestrogen-Resistant Breast Cancer Cells

  2004cites this paper
• Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats

  2004cites this paper
• Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen.

  2003cites this paper
• Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients

  2003cites this paper
• Open label trial of tamoxifen in scleroderma.

  2003cites this paper
• Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen.

  2003cites this paper
• Estrogenic Effects of Toremifene and Tamoxifen in Postmenopausal Breast Cancer Patients

  2003cites this paper
• Cellular and molecular pharmacology of antiestrogen action and resistance.

  2001cites this paper
• Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001.

  2001cites this paper
• The Role of Estrogen Receptors in Breast Cancer Metastasis

  2001cites this paper
• Effects of tamoxifen on oxyhemoglobin-induced cerebral vasoconstriction.

  2000cites this paper
• Molecular markers for predicting response to tamoxifen in breast cancer patients

  2000cites this paper
• Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy.

  2000cites this paper
• Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients

  2000cites this paper
• Meta‐analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer

  1999cites this paper
• The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer

  1999cites this paper
• Update on the management of advanced breast cancer.

  1999cites this paper
• The academic global virtual concept in clinical cancer research and its application to breast cancer: The Breast Cancer International Research Group.

  1999cites this paper
• Pharmacology and Use of Antiestrogens in Treatment and Chemoprevention of Breast Cancer

  1999cites this paper
• Autoantibodies to the nuclear phosphoprotein nucleophosmin in breast cancer patients.

  1998cites this paper
• Tamoxifen in the treatment of breast cancer.

  1998cites this paper
• Tamoxifen in the Treatment of Breast Cancer

  1998cites this paper
• Autoantibodies to the Nucleolar Phosphoprotein Nucleophosmin in Breast Cancer Patients

  1998cites this paper
• Pharmacokinetic study of low- versus high-dose medroxyprogesterone acetate (MPA) in women

  1998influential citation
• Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.

  1998cites this paper
• A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer

  1997cites this paper
• Adjuvant Drug Treatment for Resectable Breast Cancer.

  1997cites this paper
• Tamoxifen Metabolism and Oestrogen Receptor Function - Implications for Mechanisms of Resistance in Breast Cancer

  1996cites this paper
• Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats.

  1996cites this paper
• Use of tamoxifen for breast cancer: twenty-eight years later.

  1995cites this paper
• Natural interferon-beta and tamoxifen in hormone-resistant patients with advanced breast cancer.

  1995cites this paper
• Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.

  1995cites this paper
• Effect of tamoxifen on carbachol-triggered intracellular calcium responses in chicken granulosa cells.

  1994cites this paper
• Inhibiting intracellular signalling as a strategy for cancer chemoprevention.

  1994cites this paper
• Escalating drug delivery in cancer chemotherapy: a review of concepts and practice--Part 1.

  1993cites this paper
• Molecular Oncology and Clinical Applications

  1993cites this paper
• Review article : Hormone treatments in the common 'hormone-dependent' carcinomas

  1993cites this paper
• Endocrine Treatment of Malignant Disease

  1993cites this paper
• Escalating drug delivery in cancer chemotherapy: a review of concepts and practice--Part 2.

  1993cites this paper
• Breast cancer patients--the support given by nurses.

  1993cites this paper
• Does the breast cancer dollar make sense?

  1992cites this paper
• Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.

  1992cites this paper
• Die palliative Hormontherapie des Mammakarzinoms

  1991cites this paper
• Tamoxifen in premenopausal patients with metastatic breast cancer: a review.

  1991cites this paper
• Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer.

  1990cites this paper
• Long-term adjuvant tamoxifen therapy for breast cancer: the prelude to prevention.

  1990cites this paper
• Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture.

  1990cites this paper
• Endocrine pharmacology of antiestrogens as antitumor agents.

  1990cites this paper
• Overview of hormonal therapy in advanced breast cancer.

  1990cites this paper
• Endocrine treatment of breast cancer in women.

  1990cites this paper
• Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

  1989cites this paper
• The use of endocrine therapy.

  1989cites this paper
• The value of high dose tamoxifen in postmenopausal breast cancer patients progressing on standard doses: a pilot study.

  1988cites this paper
• Anti-oestrogens in the treatment of breast and gynaecological cancers.

  1988cites this paper
• The clinical biology of hormone-responsive breast cancer.

  1988cites this paper
• The bioavailability of Tamoplex® (tamoxifen)

  1988cites this paper
• Advanced breast cancer--new approaches to treatment: workshop report.

  1988cites this paper
• Complete remission following endocrine or combined cytotoxic and hormonal treatment in advanced breast cancer. A retrospective analysis.

  1987cites this paper